

# ***Beyond Heartburn: Evaluation and Management of Extraesophageal Manifestations of GERD***

**Michael R. Mills, MD, MPH, FASGE, AGAF, FACG**

Clinical Associate Professor of Medicine, UA-COM Phoenix  
Director, Swallowing and Reflux Center, Digestive Institute BUCMP  
Director, Community Integration  
Arizona Digestive Health, PC





No financial disclosures



# Learning Objectives

1. Extraesophageal signs + symptoms linked to Gastroesophageal Reflux Disease (GERD).
2. Is “extraesophageal reflux” (EER) the cause?
3. Current treatment options for extraesophageal manifestations of GERD
4. 2018 Clinical Practice Updates

# What is “GERD”?

Gastroesophageal Reflux Disease

**Montreal Consensus definition:** *a condition which develops when the reflux of gastric content into the esophagus causes troublesome symptoms and/or complications (stricture, Barrett’s esophagus). Syndromes include:*

Typical reflux syndrome -- heartburn and/or regurgitation;  
may include epigastric pain / sleep disturbance


Reflux chest pain -- “non-cardiac chest pain”

Extra-esophageal reflux syndromes (EER, laryngopharyngeal reflux = LPR)

→ .... with established association including cough, asthma,  
laryngitis/voice issues, and dental erosions

.... without established association including sinusitis, pharyngitis,  
Idiopathic Pulmonary Fibrosis, recurrent otitis media

# Erosive Esophagitis



# *It's not "just" heartburn!*

## GERD Facts


COMMON: 30-40% US weekly; 20% in US have GERD  
\*7% daily reflux = 275,000 in Phoenix!

COSTLY: \$15 bl/yr for GERD + \$50 bl/yr atypical sx  
and impact on HRQOL

CHRONIC: 75% patients have recurrent symptoms

COMPLEX: Barrett's => esophageal cancer; stricture  
→ atypical / extraesophageal symptoms

# “Discovery” of EER



Contact ulcer hypothesized to be due to acid reflux

*Cherry J; Margulies SI Laryngoscope (1968)*

# The “Silent Reflux” Craze

- 1979 Anti-reflux surgery stops aspiration + GERD
- 1991 Koufman - 225 patients & extensive lit. review  
Strongly suggested GERD caused EER.

*.....based on small observational/case controlled studies*

- 2002 American Academy Otolaryngology-H&N Surg  
*Committee on Speech, Voice + Swallowing Disorders*  
Dx made by
  - Laryngoscopy findings (RFS > 7)
  - Patient’s symptoms (RSI > 13)
  - Positive pH probe testingREC: PPI BID x 6 months (+ see GI doc for EGD)

*Pellegrini CA, Demeester TR (et al) Surgery (1979)*

*Koufman JA. Laryngoscopy (1991)*

*Koufman JA, Aviv JE, Casiano RR (et al)*

*Otolaryngol Head Neck Surg (2002)*







# Signs & Symptoms blamed on Reflux

## Laryngopharyngeal

Hoarseness

Globus sensation

Sore/burning throat

Chronic throat clearing

Laryngeal cancer

Laryngitis/ulcer/nodules/stenosis

## Respiratory

Chronic cough

Asthma

Pneumonia

Pulmonary fibrosis

Lung Tx rejection

## Other

Dental erosions

Otitis

Chronic sinusitis

Post nasal drip

Chest pain

*Vaezi MF, Katzka D, Zerbib F Clin Gastroenterol Hepatol (2018)*


*Katz PO, Gerson LB, Vela MF Am J Gastro (2013)*



# Proposed Pathophysiology

Direct contact of refluxate (acid) into areas that lack protective defensive mechanisms.

*But subsequent studies failed to demonstrate a clear causal relationship with ACID reflux due to mixed results from PPI and pH data.*



# Refluxate Link Challenges


- Refluxate Contents
  - *Acid (pH<4) - how much ?*
  - *Weak Acid (pH 4-6) ?*
  - *Pepsin*
  - *Bile ?*
  - *Liquid and / or Gas forms ?*
- Quantity of refluxate
  - *Frequency / Duration (total time or long episode ?)*
  - *Supine or upright position?*
- Location differences ?
  - *How/What and When and Where to measure ?*
- Other factors
  - *Esophageal clearance / motility ?*
  - *UES pressures ?*



Cough elicited by:

ESOPHAGEAL DISTENTION

ESOPHAGEAL ACID  
PERFUSION




Smith JA, Decalmer S, Kelsall J et al *Gastro* (2010)

# Direct and Central Neuronal Pathways

- Central effect of reflux bolus activates neurons -> bronchial constriction leading to cough; acid infusion in esophagus
- Sensitizes pharyngeal and respiratory afferent pathways.
- Reflux - > Cough = Cough -> Reflux
- Sensory changes; irritable or hypersensitive larynx.

*Smith JA, Decalmer S, Kelsall J et al Gastro (2010)*

# Esophageal-Bronchial Reflex



Houghton LA, Lee AS, Badri H et al  
*Nat Rev Gastroenterol Hepatol* (2016)



*As of 2018..... there are no criteria (or diagnostic tests) that unequivocally demonstrates a causal link between GERD & EER signs and symptoms.*







# Extraesophageal Reflux Evaluation




THE UNIVERSITY  
OF ARIZONA



Banner  
University Medical Center  
Phoenix Campus

# Reflux Symptom Index



**Within the last MONTH, how did the following problems affect you?**      **0 = No Problem    5 = Severe Problem**

	0	1	2	3	4	5
Hoarseness or a problem with your voice	0	1	2	3	4	5
Clearing your throat	0	1	2	3	4	5
Excess throat mucous or postnasal drip	0	1	2	3	4	5
Difficulty swallowing food, liquids, or pills	0	1	2	3	4	5
Coughing after you ate or after lying down	0	1	2	3	4	5
Breathing difficulties or choking episodes	0	1	2	3	4	5
Troublesome or annoying cough	0	1	2	3	4	5
Sensations of something sticking in your throat or a lump in your throat	0	1	2	3	4	5
Heartburn, chest pain, indigestion, or stomach acid coming up	0	1	2	3	4	5
<b>Your RSI is</b>						

A score of 15 or more means that you have a 90% chance of having reflux, especially airway reflux.

Validated in patient with symptoms; before/after PPI Tx


Belafsky, PC, Postma GN, Koufman JA et al J Voice (2002)  
<http://www.voiceinstituteofnewyork.com/>







# Diagnostic Tests

- Laryngoscopy
- Esophagogastroduodenoscopy (EGD)
- Ambulatory pH monitoring (BRAVO)
- Combined pH-impedance monitoring
- Novel tests
  - salivary pepsin
  - mucosal impedance

# Findings at Laryngoscopy



1. Posterior pharyngeal wall
2. Interarytenoid bar
3. Posterior commissure
4. Posterior cricoid wall
5. Arytenoid complex
6. True vocal folds
7. False vocal folds
8. Anterior commissure
9. Epiglottis
10. Aryepiglottic fold



# Reflux Finding Score (RFS)

*mucosal injury at laryngoscopy*

1. Subglottic edema	0 = absent 2 = present	2. Ventricular Obliteration	2 = partial 4 = complete
3. Erythema/hyperemia	2 = arytenoids only 4 = diffuse	4. Vocal fold edema	1 = mild 2 = moderate 3 = severe 4 = polypoid
5. Diffuse laryngeal edema	1 = mild 2 = moderate 3 = severe 4 = obstructing	6. Granuloma/granulation tissue	0 = absent 2 = present
7. Posterior commissure hypertrophy	1 = mild 2 = moderate 3 = severe 4 = obstructing	8. Thick endolaryngeal mucus	0 = absent 2 = present

***RSF > 7 = Laryngeal Pharyngeal Reflux (LPR)***

*Belafsky, PC, Postma GN, Koufman JA et al  
Laryngoscope (2001)*



# Findings at Laryngoscopy

Early studies – uncontrolled in pts w/ GERD + LPR

Suggested that REFLUX was the cause of Laryngeal stenosis (78%), Laryngeal cancer (71%), Laryngitis (60%), Globus sensation (58%), and Cough (52%)

But...

In asymptomatic (normal) patients, up to 86% had one of the “LPR” laryngoscopic findings.

Studies mixed intra-/ interobserver reproducibility

*Koufman JA. Laryngoscopy (1991)*


*Hicks, DM, Ours TM, Abelson TI et al. J Voice (2002)*

*Vaezi MF, Hicks DM, Abelson TI et al*

*Clin Gastroenterol Hepatol (2003)*



# Limited Value of Laryngopharyngeal Lesions + GERD/Erosive Esophagitis



Vavricka, SR, Storck CA, Wildi SM Am J Gastro (2007)





# Laryngoscopic Findings Summary

Including the Reflux Finding Score (RFS):

- Does not correlate well with traditional pH tests
- Does not distinguish normal from pts w/disease
- Does not predict response to PPI therapy compared to placebo.

\*poor predictive value in determination of cause



# Upper endoscopy (EGD)


- Erosive esophagitis (EE) can be found in up to 40% of patients with asthma
- EE can be found in 20% patient with primary extraesophageal symptoms / silent reflux

> However, minority of patients with EE have extraesophageal reflux / LPR symptoms

\*poor predictive value in determination of cause

*(EGD valuable for evaluation of Barrett's esophagus, dysphagia, hernia size/type)*

# Ambulatory pH-Z Testing & Manometry




pH



HRM ESO

# Anatomy of Upper GI Tract





## Upper Esophageal Sphincter

- 3 cm long
- Resting Pressure – 34 – 104 mm Hg

## Lower Esophageal Sphincter

- Located in distal 3-5 cm of esophagus
- Resting pressure – 13 – 43 mmHg
- Serves to reduce gastric reflux and regurgitation

# Normal Swallow



# pH-Impedance Testing with Symptom Correlation

- pH -- Transnasal Catheter vs BRAVO capsule
  - ON PPI to confirm acid control
  - OFF PPI to confirm GERD
- Impedance testing
- Symptom Correlation

# Catheter pH Testing with IMPEDANCE ("Z")

**Digitrapper<sup>®</sup> pH-Z**  
Ambulatory 24-Hour pH & Impedance Recorder

**Digitrapper<sup>®</sup> pH-Z** **AccuView<sup>®</sup> pH-Z**

Please reference the provided User Manuals for the Digitrapper pH-Z and AccuView software for a more detailed explanation of operation.

## QUICK GUIDE



### RECORDING

#### START PROCEDURE

1. Remove the recorder from the carrying case. (see Below)
2. Place two new AA (Alkaline Only) batteries in the battery compartment and place the recorder back into the carrying case.
3. Press any button to turn the recorder on.
4. Insert a catheter into the appropriately labeled connector, ensuring it locks in place.
5. Set catheter type, study duration, and other parameters in the "Settings" menu.
6. Start a new study by selecting "Start Study" from the Main Menu and follow the on-screen messages to confirm starting a new study.
7. Prior to calibration, place sensor(s) in pH buffer solution or saline for a minimum of 10 minutes.
8. Follow on screen instructions for calibration, refer to the User Manual for more detailed instructions.
9. Use the pH readings on the "Ready for Intubation" screen to aid in intubation.




5757 W. Century Blvd., Ste 660  
Los Angeles, CA 90045  
USA  
Tel: +1 310 641 8492  
Toll Free: +1 866 641 8492  
Fax: +1 310 872 5558  
www.altrainst.com

110100-04







# Bravo 48-96 hour Wireless pH Testing





Extended capsule-based  
pH monitoring



now captures  
to 96 continuous  
are.

extended recording  
improves the diagnostic  
to day variability'  
events both on and off  
events with refractory  
on because a regular



 Banner  
University Medical Center  
Phoenix Campus

# What is IMPEDANCE (“Z”) ?

Resistance to conductivity on 2 points of catheter:

- liquid rich in ions causes drop in impedance


Can determine direction of liquid in each event

- from mouth to stomach (normal) or refluxing.


Normal numbers established distally; not for LPR....

Assess # acid, weak acid, and non-acid reflux events


# Normal pH-Z




# + pH testing (distal only)



# Distal and Proximal Reflux



# Proximal pH-Z Event



# Limitations of pH-Z studies

Abnormal distal esophageal pH does not predict response EER symptoms to PPI therapy


Even with dual probe catheters, fully off PPI's:

- Technical difficulties of proper placement
  - oropharynx (Restech Dx-pH device) vs. dual cath
- Swallow artifacts (> 90% drop in pH due to swallows)
- Lack of agreement of normal proximal values

# Bifurcated esophageal and pharyngeal pH-impedance catheter on / off PPI

Results Not  
Reproducible

Pharyngeal pH




Pharyngeal impedance

Proximal esophageal impedance

Results  
Reproducible

Esophageal pH



Distal esophageal impedance

Zerbib F, Roman S, Des Varannes SB et al  
*Clin Gastroenterol Hepatol* (2013)



# Restech vs. MII/pH

Study evaluated 22 patients Restech results and response to PPI's.

- 9 patients had + Restech results, all 9 responded to PPI = PPV 100%
- 13 patients had – Restech results, 4 responded to PPI; 9 non-respond suggesting a NPV 69%.

Simultaneous Oropharyngeal (Restech) and MII/pH testing

- 515 reflux episodes on MII/pH
- 180 in hypopharynx / 41% no change pH (non-acid refluxate)
- Restech only noted 39 acid events
  - 17 events were swallows according to MII (43.6%)
  - 15 events were not associated with impedance or pH change

ONLY 7 episodes detected with both techniques (1.3% capture rate)

**\*Restech cannot be recommended as validated tool for EER/LPR**

*Vailaiti C, Mazzoleni G, Bondi S et al J Voice (2012)*

*Ummarino D, Vandermeulen L, Roosens B et al*

*Laryngoscope (2012)*

# Patient Symptoms Association with Reflux

Marking of event times / symptoms on device:


- Meal times excluded (increase acid secretion)
- Awake & Sleeping (supine) have specific norms
- Specific symptoms compared to reflux events:
  - \* SI = symptom index (>50% events noted)
  - \* SAP = symptom associated probability  
> 95% +ve association (Fisher Exact Test)

# Event Monitoring Challenges

## Simultaneous Cough and Reflux Recording.....

- Up to 90% cough events are not adequately reported by the patient via event recorder.
- Reflux->Cough // Cough->Reflux similar #'s.

Most laryngeal symptoms are not sudden onset, such as the symptom of heartburn.



Smith JA, Decalmer S, Kelsall J et al Gastro (2010)

# Summary pH-Z testing in patients with EER Symptoms

- Dual channel pH-impedance is the best tool
  - Use BRAVO if patient cannot tolerate catheter
- Off PPI therapy (5-10 days)
- Consider **positive study** if there is:
  - Increased distal esophageal acid exposure
  - Increased proximal acid exposure (2-3%?)
- Possibly positive if:
  - + Symptom Associated Probability w/nl acid exposure
  - Proximal impedance events – may be important

# Salivary Pepsin

For GERD: Sensitivity 79%; Specificity 65%

PPV = 78%; NPV = 81%

*- but wide variations in values time of day*

For LPR: Sensitivity 78%; Specificity 53% = predict high RFS + severity laryngeal irritation

However, study 50 children: 42% had abnl pepsin but no correlation with EER sx and pH-Z tests.

**\*Role salivary pepsin remains to be established**

*Sarita Yuksel E, Hong SK, Strugala V et al Laryngoscope (2012)*

*Yadlapati R, Adkins C Jaiyeola DM et al*

*Clin Gastroenterol Hepatol (2016)*

*Dy F, Amirault J, Mitchell RD, et al J Pediatr (2016)*



# Mucosal Impedance

- Probe placed during EGD (catheter or balloon-based) can measure changes in mucosal current conduction to assess mucosal integrity (i.e. injury)
- Well described GERD and Eosinophilic Esophagitis
- Recent study described MI can also predict EER patients and pathologic reflux

\*Further studies are needed

# Testing Summary

No single diagnostic test is able to unequivocally confirm reflux as cause of EER signs + symptoms

*.....there may be value in combining several diagnostic test results with clinical presentation to identify a subset of patients where reflux could be causal of EER signs + symptoms*




# Treatment

- Lifestyle Modifications
- Medical Therapy
  - H2 blockers
  - Alginates
  - PPI
  - Prokinetic
  - Baclofen
  - Neuromodulating agents
- Endoscopic Antireflux Procedures
- Surgery

# Lifestyle Modifications

REDUCE WEIGHT !



NON-LINEAR RELATIONSHIP BETWEEN GERD AND ACID EXPOSURE IN THE EXTRAESOPHAGEAL MANIFESTATIONS OF RELFUX

Aslam M, Slaughter JC, Goutte M et al  
*Clin Gastroenterol Hepatol* (2012)  
Fraser-Moodie CA, Norton B, Gornell C et al  
*Scan J Gastroenterol* (1999)

# Lifestyle Modifications

*With supine regurgitation / nocturnal reflux:*

- Elevate head of bed
- Avoid eating late (> 4 hours before bedtime)

Remove offending food items

- “Trigger” foods
- Acid/spicy foods, soda, caffeine, alcohol, smoking

Avoid reflux-promoting meds

# Medical Therapy


## Acid Suppression

- Antacids and Alginic Acid\* – temporary relief
- H2RAs BID dosing heal esophagitis (EE) - 50%
  - Pre-PPI studies with conflicting results (in asthma)
- Proton Pump Inhibitors (PPI) are superior to H2RAs, sucralfate, & placebo in healing EE and relief of heartburn. Standard of care for GERD

# PPIs in Asthma

Early enthusiasm – small, open label studies with variable end points

## Effect of Omeprazole on Asthma Symptom Score



27% of patients required >20 mg/d of omeprazole to control reflux.

# PPIs in Asthma

412 RAD pts randomized to PPI BID vs. placebo  
found no difference between groups at 24 wks.

*Suggestion a subgroup patients with both  
nocturnal respiratory and reflux symptoms may  
benefit from PPI therapy.*

*Mastrorade JG, Anthonisen NR, Castro M et al N Engl J Med (2009)*

# PPI for Laryngeal Symptoms

Early open label enthusiasm (47-90% improved)

Teta-analyses also demonstrate no change



*There may be a subgroup that benefit (GERD Sx)*

*Vaezi MF, Richet JE, Stasney CR et al Laryngoscope (2006)*

*Liu C, Wang H, Liu K Braz J Med Biol Res (2016)*

# PPI for Laryngitis

Early open label enthusiasm (47-90% improved with PPI therapy)



3 additional meta-analyses also failed to demonstrate benefit.

Vaezi MF, Richet JE, Stasney CR et al *Laryngoscope* (2006)  
 Liu C, Wang H, Liu K, Braz J, *Med Biol Res* (2016)  
 Qadeer, MA, Phillips CO, Lopez AR et al *Am J Gastro* (2006)



# Summary PPI and EER

Those with suspected extraesophageal reflux who also have typical GERD symptoms may be the subset to respond to PPI therapy.

Lack of benefit of PPI BID for 1-2 months trial & without regurgitation to suggest nonacid reflux, GERD can be excluded, and a search for other causes pursued.

# Other Agents for EER

Promotility Agents – enhance clearance

Baclofen – inhibits LESRS

Alginates – forms pH-neutral raft




*\* More data needed to make recommendation*

*Glicksman JT, Mick PT, Fung K et al Laryngoscope (2014)*

*McGlashan JA, Johnstone LM, Sykes J et al*

*Eur Arch Otorhinolaryng (2009)*



# Surgery

Surgical data for EER symptoms are uncontrolled retrospective, + small sample size (50-78% impr)


Best predictor is prior response to PPI therapy.

*Laryngeal symptoms unresponsive to PPI Tx do not respond to fundoplication (10% vs 7% -1 yr)*

-> Select patients may benefit with hiatus hernia, +pH-Z, and problems with regurgitation

*Swoger J, Ponsky, Hicks DM et al Clin Gastroenterol Hepatol (2006)*

## TIF Procedure Overview



©2015 AGA Institute. Hunter JG, et al. Gastroenterology. 2015 Feb;148(1):325.

### STEP 1

The EsophyX® device is inserted into the esophagus through the mouth and is positioned at the junction of the stomach and esophagus. A small hiatal hernia is reduced by engaging suction (invaginator) and positioning the esophagus below the diaphragm.

### STEP 2

A full thickness tissue fold at the gastroesophageal junction is retracted, wrapped and anchored using SerosaFuse® implantable fasteners—equivalent to 3.0 sutures—which are delivered across the tissue to complete the plication.

### STEP 3

The valve is extended and multiple fasteners (12-20) are delivered with a single device insertion. The TIF procedure reconstructs the primary components of the antireflux barrier, creating a tight 3-5 cm valve enveloping the distal esophagus below the diaphragm.

# Guidelines

- 2008 GI guidelines diverged from ENT's due to:
- Lack of clear understanding of causation
  - Uncertain diagnostic criteria (What is LPR?)
    - variable data measured and variable response to Tx
    - variable data / results of pH studies
    - LPR laryngeal changes found in 80% asymptomatic pts
    - Well done studies are lacking.
  - High placebo response with PPI studies
  - Other effects of PPI therapy

*Kahrilas PJ, Shaheen NJ, Vaezi MF (et al) Gastro (2008)*

# Clinical Practice Guideline: Hoarseness (Dysphonia) – 2018

*American Academy of Otolaryngology – Head and Neck  
Surgery Foundation (Expert multidisciplinary panel)*

## ETIOLOGIES

*Stachler RJ; Francis, DO; Seth R. Schwartz SR, et al  
Otolaryngol Head Neck Surg (2018)*



**Table 6.** Etiologies of Dysphonia and Examples from Each Category.<sup>a</sup>

Etiologic Category	Examples
Surgery	Thyroidectomy or parathyroidectomy Anterior spine surgery Thoracic and cardiac surgery Neurosurgery and skull base surgery
Inflammatory	Tobacco use Polypoid corditis Allergy
Autoimmune	Granulomatosis with polyangiitis Sarcoidosis Amyloidosis Rheumatoid arthritis
Infectious	Viral upper respiratory infection Bacterial infection Laryngeal candidiasis
Neurologic	Laryngeal dystonia (eg, spasmodic dysphonia) Vocal fold paralysis Essential tremor Parkinson disease
Endocrinologic	Hypothyroidism Diabetes Menopause Androgen supplementation
Neoplastic	Laryngeal squamous cell carcinoma Recurrent respiratory papillomatosis Metastatic disease Other neoplasms (eg, chondromas, lymphoma)
Congenital	Laryngeal web Vocal fold cyst Laryngeal cleft
Traumatic	Laryngeal fracture Posterior glottic stenosis Intubation injury
Behavioral	Vocal fold nodules Vocal fold cyst Vocal fold polyp Vocal fold vascular lesion
Musculoskeletal	Muscle tension dysphonia Cervicalgia
Gastrointestinal	Reflux ←

<sup>a</sup>Not a comprehensive list of etiologic examples.



# Clinical Practice Guideline: Hoarseness (Dysphonia) – 2018

## HISTORY TAKING

**Table 5.** Examples of Pertinent Questions in the Assessment of a Patient with Dysphonia.<sup>301,459,460,a</sup>

Voice-specific questions	<ul style="list-style-type: none"> <li>Was the onset of your hoarseness abrupt or slowly progressive?</li> <li>Does your voice ever return to normal, or is the hoarseness constant?</li> <li>Did your voice change at the time or persist after an upper respiratory tract infection?</li> <li>Do you have pain, or is there effort when talking?</li> <li>Does your voice deteriorate or fatigue with use? What is different about the sound of your voice?</li> <li>Do you have a difficult time getting loud or projecting?</li> <li>Have you noticed changes in your pitch or range?</li> <li>Do you run out of air when talking?</li> <li>Does your voice crack or break?</li> <li>Were you intubated prior to dysphonia onset?</li> <li>Did you have brain, spine, neck, or chest surgery prior to dysphonia onset?</li> <li>Did you recently take inhaled medications, antibiotics, or steroids?</li> <li>Do you need the voice for your occupation? Do you have significant daily voice use requirements?</li> <li>Do you smoke (tobacco, vape, or use recreational drugs)?</li> <li>Does your throat feel dry?</li> <li>Have you undergone radiation therapy to the head and neck region?</li> <li>Do you have any neurologic or arthritic problems?</li> <li>Did you have prior trauma (physical, emotional, or psychological) preceding the voice change?</li> </ul>
Symptoms	<ul style="list-style-type: none"> <li>Globus pharyngeus (persisting sensation of lump in throat)</li> <li>Dysphagia</li> <li>Sore throat</li> <li>Chronic throat clearing</li> <li>Cough</li> <li>Odynophagia (pain with swallowing)</li> <li>Nasal drainage</li> <li>Postnasal drainage</li> <li>Acid reflux</li> <li>Regurgitation</li> <li>Heartburn</li> <li>Hemoptysis</li> <li>Nonanginal chest pain</li> <li>Waterbrash (sudden appearance of salty liquid in the mouth)</li> <li>Halitosis ("bad breath")</li> <li>Weight loss</li> <li>Night sweats</li> <li>Fever (&gt;101.5°F)</li> <li>Otalgia (ear pain)</li> <li>Dyspnea (difficulty breathing)</li> </ul>
Medical history relevant to dysphonia	<ul style="list-style-type: none"> <li>Occupation and/or avocation requiring extensive voice use (eg, teacher, singer)</li> <li>Absenteeism from occupation due to dysphonia</li> <li>Prior episodes of hoarseness</li> <li>Relationship of instrumentation (eg, intubation) to onset of dysphonia</li> <li>Relationship of prior surgery to neck or chest to onset of dysphonia</li> <li>Cognitive impairment (requirement for proxy historian)</li> <li>Anxiety, depression, stress</li> </ul>
Acute conditions	<ul style="list-style-type: none"> <li>Infection of the throat and/or larynx: viral, bacterial, fungal</li> <li>Foreign body in larynx, trachea, or esophagus</li> <li>Neck or laryngeal trauma</li> </ul>
Chronic conditions	<ul style="list-style-type: none"> <li>Stroke</li> <li>Diabetes</li> <li>Parkinson's disease</li> <li>Parkinson-plus syndromes (eg, progressive supranuclear palsy)</li> <li>Myasthenia gravis</li> <li>Multiple sclerosis</li> <li>Amyotrophic lateral sclerosis</li> <li>Essential tremor</li> <li>Testosterone deficiency</li> <li>Allergic rhinitis</li> <li>Chronic rhinitis</li> <li>Hypertension (because of certain medications used for this condition)</li> <li>Schizophrenia (because of antipsychotics used for mental health problems)</li> <li>Osteoporosis (because of certain medications used for this condition)</li> <li>Asthma (because of use of inhaled steroids or effect on respiratory function)</li> <li>Chronic obstructive pulmonary disease (because of use of inhaled steroids or effect on respiratory function)</li> <li>Aneurysm of thoracic aorta (rare cause)</li> <li>Laryngeal cancer</li> <li>Lung cancer (or metastasis to the lung)</li> <li>Thyroid cancer</li> <li>Hypothyroidism and other endocrinopathies</li> <li>Vocal fold nodules</li> <li>Vocal fold paralysis</li> <li>Vocal abuse</li> <li>Infective laryngitis</li> <li>Chemical laryngitis</li> <li>Chronic tobacco use</li> <li>Sjogren's syndrome</li> <li>Alcohol (moderate to heavy use or abuse)</li> <li>Menopause</li> </ul>

Stachler RJ; Francis, DO; Seth R. Schwartz SR, et al  
*Otolaryngol Head Neck Surg* (2018)



<sup>a</sup>These are sample considerations, and the list is not comprehensive of all pertinent parameters that may need to be assessed.



# Clinical Practice Guideline: Hoarseness (Dysphonia) - 2018

**Table 7.** Medications That May Cause Dysphonia.<sup>a</sup>

Medication	Mechanism of Impact on Voice
Coumadin, thrombolytics, phosphodiesterase-5 inhibitors	Vocal fold hematoma <sup>461-463</sup>
Bisphosphonates	Chemical laryngitis <sup>464</sup>
Angiotensin-converting enzyme inhibitors	Cough <sup>465</sup>
Antihistamines, diuretics, anticholinergics	Drying effect on mucosa <sup>78, 80, 345</sup>
Danocrine, testosterone	Sex hormone production/utilization; alteration <sup>466, 467</sup>
Antipsychotics, atypical antipsychotics	Laryngeal dystonia <sup>468, 469</sup>
Inhaled steroids	Dose dependent mucosal irritation <sup>261, 263, 470</sup> ; fungal laryngitis <sup>264, 265</sup>

<sup>a</sup>This is not intended to be an exhaustive list of all medication that could cause dysphonia.



# Clinical Practice Guideline: Hoarseness (Dysphonia) – 2018

## EVIDENCE-BASED STATEMENTS



**Table 4.** Summary of Evidence-Based Statements.

Statement	Action	Strength
1. Identification of abnormal voice	Clinicians should identify dysphonia in a patient with altered voice quality, pitch, loudness, or vocal effort that impairs communication or reduces QOL.	Recommendation
2. Identifying underlying cause of dysphonia	Clinicians should assess the patient with dysphonia by history and physical examination for underlying causes of dysphonia and factors that modify management.	Recommendation
3. Escalation of care	Clinicians should assess the patient with dysphonia by history and physical examination to identify factors where expedited laryngeal evaluation is indicated. These include but are not limited to recent surgical procedures involving the head, neck, or chest; recent endotracheal intubation; presence of concomitant neck mass; respiratory distress or stridor; history of tobacco abuse; and whether the patient is a professional voice user.	Strong recommendation
4a. Laryngoscopy and dysphonia	Clinicians may perform diagnostic laryngoscopy at any time in a patient with dysphonia.	Option
4b. Need for laryngoscopy in persistent dysphonia	Clinicians should perform laryngoscopy, or refer to a clinician who can perform laryngoscopy, when dysphonia fails to resolve or improve within 4 weeks or irrespective of duration if a serious underlying cause is suspected.	Recommendation
5. Imaging	Clinicians should <i>not</i> obtain computed tomography (CT) or magnetic resonance imaging (MRI) for patients with a primary voice complaint prior to visualization of the larynx.	Recommendation against
6. Antireflux medication and dysphonia	Clinicians should <i>not</i> prescribe antireflux medications to treat isolated dysphonia based on symptoms alone attributed to suspected gastroesophageal reflux disease (GERD) or laryngopharyngeal reflux (LPR), without visualization of the larynx.	Recommendation against
7. Corticosteroid therapy	Clinicians should <i>not</i> routinely prescribe corticosteroids for patients with dysphonia prior to visualization of the larynx.	Recommendation against
8. Antimicrobial therapy	Clinicians should <i>not</i> routinely prescribe antibiotics to treat dysphonia.	Strong recommendation against
9a. Laryngoscopy prior to voice therapy	Clinicians should perform diagnostic laryngoscopy, or refer to a clinician who can perform diagnostic laryngoscopy, before prescribing voice therapy and document/communicate the results to the speech-language pathologist (SLP).	Recommendation
9b. Advocating for voice therapy	Clinicians should advocate voice therapy for patients with dysphonia from a cause amenable to voice therapy.	Strong recommendation
10. Surgery	Clinicians should advocate for surgery as a therapeutic option for patients with dysphonia with conditions amenable to surgical intervention, such as suspected malignancy, symptomatic benign vocal fold lesions that do not respond to conservative management, or glottic insufficiency.	Recommendation
11. Botulinum toxin	Clinicians should offer, or refer to a clinician who can offer, botulinum toxin injections for the treatment of dysphonia caused by spasmodic dysphonia and other types of laryngeal dystonia.	Recommendation
12. Education/prevention	Clinicians should inform patients with dysphonia about control/preventive measures.	Recommendation
13. Outcomes	Clinicians should document resolution, improvement, or worsened symptoms of dysphonia or change in QOL among patients with dysphonia after treatment or observation.	Recommendation

# GI: Extraesophageal GERD 2018 Clinical Practice Update

## Best Practice Advice:

1. Role GI doc .... to evaluate for GI causes.
2. Evaluation by ENT, pulm, and/or allergy are essential, often should be the initial visits due to the multifactorial and many non-GI causes of symptoms.
3. Empiric therapy with aggressive PPI x 6-8wks can help w/ ? is reflux + EER
4. No single test exists to definitively identify reflux as etiology for possible EER.
5. Constellation pt's presentation, dx test, and response to therapy should be employed in determination if reflux is possible etiology of EER symptoms.
6. Lack of response to PPI + nl pH off PPI (or nl impedance on PPI) significantly reduced the likelihood that reflux is a contributing etiology to EER symptoms
7. Surgical fundoplication is discourage in pt's w/EER Sx and no response to PPI
8. Fundoplication reserved for those with hiatus hernia, +pH, and continued Sx

# Summary

- Reflux may be culprit in a subgroup of EER pts.
- In many patients, cause is multifactorial and  
→ evaluation by ENT, allergy, and pulmonary
- Role of diagnostic testing:
  - Establish presence and severity of reflux
  - Assess likelihood link to patient's symptoms
- If no response to PPI therapy, investigate alternative causes.

